Roeloffzen, Wilfried
University Medical Center Groningen · National and Kapodistrian University of Athens · St. Antonius Ziekenhuis · Erasmus MC Cancer Institute · Amsterdam University Medical Centers · University of Turin · Vrije Universiteit Amsterdam · Amsterdam UMC Location Vrije Universiteit Amsterdam
5 papers on CoChatORCID 0000-0003-3976-8001
Most cited papers
- Verified
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsCAR-T cell therapy research
Cited by 827
- Verified
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 599
- Verified
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., et al. (2022) · Leukemia
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 252
- Verified
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Van De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., et al. (2022) · Blood
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 25
- Verified
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
van de Donk, N. W. C. J., Agha, M. E., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W., Schecter, J. M., De Braganca, K. C., Varsos, H., et al. (2022) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free